OVERVIEW

Acute and Chronic Rhinosinusitis: A Comprehensive Review is organized by Icahn School of Medicine at Mount Sinai (ISMMS) and will be held from Jan 16, 2018 - Jan 16, 2020.

Target Audience:
Otolaryngology

CME Credits Offered: 1.75

Course Overview:
This course, offered by the Department of Otolaryngology – Head and Neck Surgery at the Icahn School of Medicine at Mount Sinai, is designed to inform primary care physicians and general otolaryngologists, as well as nurses, physician assistants and medical assistants, about the differences between acute and chronic rhinosinusitis and how to distinguish and treat them. It is also applicable to individuals who wish to broaden their knowledge and vernacular about this disease process, especially those who may suffer from this condition. The course has been divided into four modules, each of which is followed by multiple choice questions to help attendees further understand this condition:

Week 1 - CME Information, Accreditation and Introduction
Week 2 - Module 1: Normal Sinus Anatomy and Function (15 min. + quiz)
Week 3 - Module 2: Acute Rhinosinusitis: Diagnosis and Treatment (17 min. + quiz)
Week 4 - Module 3: Chronic Rhinoinusitis: Diagnosis and Treatment (18 min. + quiz)
Week 5 - Module 4: The Role of Surgery for Sinusitis and Activity Evaluation (36 min. + 2 quizzes)

The primary objective of this course is to provide physicians with a thorough understanding of how to better diagnose and treat patients who suffer from acute and chronic rhinosinusitis.

Objectives:
• Identify dormant tumor cells nodes in neck dissection specimens obtained from patients who underwent primary surgical resection through the use of cytokeratin antibody and explain margins for markers associated with dormancy-inducing signaling pathways.
• Identify the need for a new classification system of sinonasal sarcoidosis that will help serve as a guide for both diagnosis and treatment options. Also, explain surgical and medical management of various sinus diseases.
• Explain to patients the benefit the benefit of this existing clinical trial (de- escalating XRT and chemo/XRT regimens and, thus, decreasing toxicity) among HPV- oral cancer patients and enhance long term disease control via the advaxis vaccine. Secondary objective is to identify those who can benefit from enrollment.

Additional details will be posted as soon as they are available.